Thymosin Beta 4 & Related Research Studies - Biotech Peptides

Thymosin Beta-4 Ophthalmic Solution for Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Clinical Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4445951/ Thymosin β4 Significantly Improves Signs and Symptoms of Severe Dry Eye Diseasehttps://pubmed.ncbi.nlm.nih.gov/25826322/ RGN-259 Thymosin β4 Improves Clinically Important Dry Eye Efficacy Measures in Comparison With Vehicle in a Phase 2 Clinical Trialhttps://www.nature.com/articles/s41598-018-28861-5 Comparative Study of Thymosin Beta-4 Eye Drops vs. Vehicle for Dry Eyehttps://clinicaltrials.gov/study/NCT01393132 Thymosin Beta-4 Accelerates Wound Healinghttps://pubmed.ncbi.nlm.nih.gov/10469335/ Thymosin Beta-4 Promotes Corneal Wound Healing and Decreases Inflammation In Vivo Following Alkali Injuryhttps://pubmed.ncbi.nlm.nih.gov/11950239/ Thymosin Beta-4 and a Synthetic Peptide Containing Its Actin-Binding Domain Promote Dermal Wound Repairhttps://pubmed.ncbi.nlm.nih.gov/12581423/ Recombinant Thymosin Beta-4 Can Promote Full-Thickness Cutaneous Wound Healing in BALB/c Micehttps://pubmed.ncbi.nlm.nih.gov/17923415/ Review Articles Thymosin β4: A Multifunctional Regenerative Peptidehttps://pubmed.ncbi.nlm.nih.gov/22074294/ Progress on the Function and Application of Thymosin β4https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/ Thymosin Beta-4 and the Eye: The Journey From Bench to Bedsidehttps://pubmed.ncbi.nlm.nih.gov/30063853/ Thymosin Beta-4: A Potential Novel Adjunct Treatment for Severe Refractory Atopic Dermatitishttps://pmc.ncbi.nlm.nih.gov/articles/PMC10403815/ Thymosin β4: A Potential Novel Dry Eye Therapyhttps://pubmed.ncbi.nlm.nih.gov/23050816/ The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice. This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information. Thymosin Beta-4 is not FDA-approved for any medical indication in the United States. Any clinical use may be considered investigational or off-label depending on context. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment. R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law. # Thymosin Alpha-1 (Tα1)

Neovascularisation of the ischaemic border zone is critical for myocardial salvage and research applications. Tβ4 promotes cardiac angiogenesis through both direct endothelial cell effects (VEGFR2-PI3K-Akt-eNOS tube formation) and indirect cardiomyocyte paracrine effects (Tβ4-treated cardiomyocytes upregulate VEGF-A secretion). HUVEC tube formation assay (Matrigel GFR, 48-well format, IncuCyte quantification): Tβ4 (100 ng/mL-1 μg/mL) comparison to VEGF-A (50 ng/mL) positive control and SU5416 VEGFR2 inhibitor (1 μM) negative control. HUVEC migration (Boyden, VEGF-A 50 ng/mL lower chamber ± Tβ4 upper chamber: establishes whether Tβ4 is a direct motogen or requires VEGF-A). In vivo angiogenesis quantification: CD31 (PECAM-1) IHC (anti-CD31, BD Pharmingen 550274) in peri-infarct zone at 7d and 28d, image analysis (vessels/mm², vessel diameter distribution by image J, angiogenic index = vessel number × mean diameter²/field area). α-SMA+CD31 co-staining distinguishes mature arterioles (indicating functional neovascularisation supporting perfusion) from capillary sprouts (early angiogenesis). Laser Doppler perfusion imaging (LDPI, Moor Instruments LDI2) of post-infarct leg (hindlimb ischaemia model alternative) provides a non-invasive angiogenesis readout suitable for longitudinal tracking.